| Radiopharmaceutical Chemistry and Applications | Lifetime | 38 | US 23 | 99.56 |
| Prostate Cancer Treatment and Research | Lifetime | 71 | US 47 | 99.72 |
| Hormonal and reproductive studies | Lifetime | 65 | US 38 | 99.42 |
| Cancer, Lipids, and Metabolism | Lifetime | 124 | US 69 | 99.39 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 104 | US 61 | 99.60 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 396 | US 212 | 99.09 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 196 | US 113 | 99.11 |
| PARP inhibition in cancer therapy | Lifetime | 86 | US 42 | 98.65 |
| Urinary and Genital Oncology Studies | Lifetime | 191 | US 111 | 98.63 |
| Urinary Bladder and Prostate Research | Lifetime | 300 | US 147 | 98.33 |
| Cancer Diagnosis and Treatment | Lifetime | 527 | US 249 | 97.41 |
| Bone health and treatments | Lifetime | 446 | US 195 | 97.92 |
| Multiple Myeloma Research and Treatments | Lifetime | 709 | US 318 | 96.62 |
| Pelvic floor disorders treatments | Lifetime | 765 | US 329 | 96.58 |
| Economic and Financial Impacts of Cancer | Lifetime | 892 | US 566 | 92.23 |
| Prostate Cancer Treatment and Research | 2021-2025 | 2 | US 1 | 99.95 |
| Hormonal and reproductive studies | 2021-2025 | 1 | US 1 | 99.74 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 3 | US 2 | 99.89 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 8 | US 2 | 99.73 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 20 | US 9 | 99.60 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 13 | US 5 | 99.69 |
| PARP inhibition in cancer therapy | 2021-2025 | 11 | US 5 | 99.66 |
| Epigenetics and DNA Methylation | 2021-2025 | 108 | US 38 | 97.62 |
| Estrogen and related hormone effects | 2021-2025 | 19 | US 12 | 97.54 |
| Cancer Research and Treatments | 2021-2025 | 32 | US 7 | 97.59 |
| Urinary and Genital Oncology Studies | 2021-2025 | 34 | US 14 | 99.04 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 711 | US 265 | 97.29 |
| Cancer Treatment and Pharmacology | 2021-2025 | 268 | US 92 | 94.74 |
| Peptidase Inhibition and Analysis | 2021-2025 | 588 | US 145 | 90.37 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 593 | US 275 | 92.28 |
| Protein Degradation and Inhibitors | 2021-2025 | 565 | US 245 | 89.63 |
| Statistical Methods in Clinical Trials | 2021-2025 | 187 | US 78 | 88.94 |
| BRCA gene mutations in cancer | 2021-2025 | 488 | US 226 | 88.56 |
| Urinary Bladder and Prostate Research | 2021-2025 | 554 | US 136 | 88.23 |
| DNA Repair Mechanisms | 2021-2025 | 598 | US 250 | 83.45 |
| Advanced Breast Cancer Therapies | 2021-2025 | 825 | US 283 | 85.31 |
| Bone health and treatments | 2021-2025 | 488 | US 77 | 81.63 |
| Genital Health and Disease | 2021-2025 | 845 | US 256 | 72.20 |
| Cell death mechanisms and regulation | 2021-2025 | 338 | US 71 | 65.35 |
| Amino Acid Enzymes and Metabolism | 2021-2025 | 609 | US 109 | 64.22 |
| Chemical Reactions and Isotopes | 2021-2025 | 777 | US 109 | 33.88 |